Modern Chinese Medicine Group Co Ltd
Modern Chinese Medicine Group Co Ltd is a pharmaceutical company that develops, produces, and sells traditional Chinese medicine products, primarily in the People's Republic of China.
Business. Modern Chinese Medicine Group Co Ltd (1643.HK) is a pharmaceutical company listed on the Hong Kong Stock Exchange. The firm operates within the healthcare sector, specifically focusing on pharmaceuticals and medical research. It generates revenue through the sale of products. Specific details regarding operating segments, headquarters location, and geographic mix are not available in the provided data.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Modern Chinese Medicine Group Co Ltd (1643.HK) is a pharmaceutical company listed on the Hong Kong Stock Exchange. The firm operates within the healthcare sector, specifically focusing on pharmaceuticals and medical research. It generates revenue through the sale of products. Specific details regarding operating segments, headquarters location, and geographic mix are not available in the provided data.
Modern Chinese Medicine Group Co Ltd has a current ratio of 8.54, indicating strong short-term liquidity, but its return on equity of -2.72% and return on assets of -2.49% suggest poor profitability and asset utilization. The company's debt-to-equity ratio is 0.0, reflecting no long-term debt obligations, but its net cash position is negative after subtracting total debt, signaling potential liquidity constraints.
The company's operating and net income are both negative, at -14.02 million and -13.56 million CNY, respectively, which is below the median for its industry. This underperformance is exacerbated by a gross profit of 23.56 million CNY, which is insufficient to cover operating expenses. The company's return on equity and return on assets are also below the industry median, indicating a lack of capital efficiency and operational effectiveness.
The company's revenue is concentrated in a single geographic region, with all disclosed revenue generated in the People's Republic of China. There is no information on segmental revenue distribution, but the lack of geographic diversification increases exposure to local economic and regulatory risks.
The company's revenue growth is not disclosed in the available data, but its negative operating and net income suggest a declining or stagnant growth trajectory. The absence of positive earnings and the lack of capital expenditures or R&D investments further indicate a lack of growth initiatives.
The company's risk profile is characterized by medium liquidity risk and low dilution risk. The negative net cash position and lack of long-term debt suggest that the company may need to raise capital in the near term, but the absence of recent equity issuances or dilution events indicates that this is not an immediate concern.
Recent filings and transcripts do not provide additional insights into the company's operations or strategic direction. The company's financial performance and risk profile remain largely unchanged from the most recent available data.
- The company has strong short-term liquidity but poor profitability and asset utilization.
- The company's debt-to-equity ratio is 0.0, but its net cash position is negative.
- The company's revenue is concentrated in a single geographic region, increasing exposure to local economic and regulatory risks.
- The company's operating and net income are both negative, indicating poor financial performance.
- The company's risk profile is characterized by medium liquidity risk and low dilution risk.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Return On Assetsnet_income / total_assets
- Modern Chinese Medicine Group Co Ltd Market data — financials · 2026-05-26
Ownership & reference
Leadership
- Hongli ZhangChief Executive Officer, Executive Director
- Xinlei SunExecutive Chairman of the Board